Local application of basic fibroblast growth factor minipellet induces the healing of segmental bony defects in rabbits.
Fibroblast growth factor (FGF) has been reported to increase the volume of callus in a fracture model of rats. There are, however, no reports of successful repair of segmental bony defects by application of an FGF solution. In this study, the effects of basic FGF on the repair of segmental bony defects in the rabbit femur were examined. Minipellet, a new drug delivery system using atelocollagen, was employed to ensure effective delivery of FGF. Segmental bony defects (10 mm in length) were created in the right femurs of 19 rabbits. In pilot studies, no defects of this size healed spontaneously within 6 weeks. Bones were stabilized with miniexternal fixators. Minipellets containing basic FGF were implanted between fragments so as to bridge the two fragments. The healing processes were monitored radiographically and studied histologically. In rabbits in which FGF was added to the defect site at doses of 1.4 microgram or higher, approximately 90% of the defects were filled with new bone and cartilage within 6 weeks after minipellet implantation. In rabbits receiving placebo minipellets, however, approximately 15% of the defects were filled by callus within 6 weeks. Furthermore, this callus did not change into mature bone. An injection of 2 microgram of FGF solution to bony defects had no effect on the repair of segmental bony defects. These findings suggest that FGF plays a role in the production of adequate volumes of callus particularly in the initial stages of fracture healing and that sustained local release enables FGF to be effective at a low dose. In summary, large segmental bony defects healed after insertion of low-dose FGF minipellets. An adequate dose of FGF and an appropriate delivery system are required for successful healing of large bony defects. These findings imply the potential value of FGF minipellets in clinical practice.
Inui
K
K
Department of Orthopaedic Surgery, Osaka City University Medical School, 1-5-7 Asahimachi Abeno-Ku, Osaka 545-8585, Japan.
Maeda
M
M
Sano
A
A
Fujioka
K
K
Yutani
Y
Y
Sakawa
A
A
Yamano
Y
Y
Kato
Y
Y
Koike
T
T
D000818:Animals; D016503:Drug Delivery Systems; D005264:Femoral Fractures / Q000188:drug therapy*; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D017102:Fracture Healing; D008297:Male; D011817:Rabbits; D051381:Rats
D016222:Fibroblast Growth Factor 2